1. Generic & Brand Names
Generic: Metronidazole
Brands: Flagyl® (global), Metrogel® (topical), Nidagel® (vaginal)
Formulations:
Tablets (250mg, 500mg)
Oral suspension (200mg/5mL)
IV infusion (500mg/100mL)
Topical gel (0.75-1%)
2. Drug Class & Mechanism
Class: Nitroimidazole antibiotic/antiparasitic
Mechanism:
Forms toxic radicals → disrupts DNA/RNA synthesis
Bactericidal against anaerobes, antiprotozoal
Spectrum:
Anaerobic bacteria: Bacteroides, Clostridioides difficile
Parasites: Giardia, Entamoeba, Trichomonas
NOT for: Aerobic bacteria or viruses
3. FDA-Approved Uses
| Condition | Key Indications |
|---|---|
| Diarrhea/Colitis | C. difficile infection (CDI) |
| Dental Infections | Acute necrotizing ulcerative gingivitis, periodontitis |
| Parasitic Infections | Giardiasis, amebiasis |
| Surgical Prophylaxis | Colorectal surgery (anaerobic cover) |
4. Dosing Regimens
| Indication | Adult Dose | Duration |
|---|---|---|
| C. difficile Colitis | 500 mg PO q8h | 10-14 days |
| Acute Gingivitis | 500 mg PO q8h | 3-7 days |
| Giardiasis | 250 mg PO q8h | 5-7 days |
| Surgical Prophylaxis | 500 mg IV pre-op + q8h × 24h | 1 day |
| Renal Adjustment: |
Severe hepatic impairment: ↓ dose by 50%
Dialysis: Give post-dialysis
5. Side Effects
| Common (≥10%) | Serious (<1%) |
|---|---|
| Metallic taste | Peripheral neuropathy (irreversible) |
| Nausea/vomiting | Seizures/encephalopathy |
| Dark urine | Pancreatitis |
| Headache | Leukopenia |
| Disulfiram-like reaction (with alcohol) | Stevens-Johnson Syndrome |
6. Black Box Warnings & Contraindications
🚫 Absolute Contraindications:
First-trimester pregnancy (Category X for trichomoniasis)
Hypersensitivity to nitroimidazoles
Alcohol consumption (risk of violent nausea/vomiting)
Critical Warnings:
Carcinogenicity: Positive in rodent studies → avoid unnecessary long-term use
CNS toxicity: Risk ↑ with high doses or history of seizures
7. Drug Interactions
| Medication | Risk | Management |
|---|---|---|
| Alcohol | Disulfiram reaction (flushing, tachycardia) | Avoid during + 72h post-treatment |
| Warfarin | ↑ INR → bleeding | Monitor INR closely |
| Lithium | ↑ Toxicity (tremor, confusion) | Avoid combo |
| Phenytoin | ↑ Phenytoin levels → toxicity | Monitor serum levels |
8. Key Clinical Applications
▶️ For Diarrhea:
First-line for:
Moderate-severe C. difficile infection
Giardia-induced traveler's diarrhea
Avoid for:
Viral diarrhea (norovirus)
Campylobacter (rising resistance)
▶️ For Dental Infections:
Used for:
Acute necrotizing ulcerative gingivitis ("trench mouth")
Aggressive periodontitis (with scaling/root planing)
Typical regimen: 500 mg q8h × 3-5 days
9. Pediatric Use
| Age | Dose for Giardiasis/CDI |
|---|---|
| >3 years | 7.5 mg/kg q8h (max 500 mg) |
| Avoid <3 yrs unless life-threatening infection |
10. Storage & Administration
Tablets: 15-30°C; protect from light
Oral suspension:
Refrigerate after reconstitution
Discard after 7 days
IV: Administer over 30-60 min; avoid PVC containers
Clinical Practice Warnings
⚠️ Alcohol Interaction:
Avoid all alcohol (including mouthwash/cough syrups) during and ≥72h after treatment
Reactions include vomiting, flushing, tachycardia
⚠️ Neurotoxicity Signs:
Stop immediately for numbness, ataxia, or seizures
⚠️ Dental-Specific Notes:
Combine with amoxicillin for odontogenic abscesses
Not for routine prophylaxis - reserve for severe anaerobic infections
✅ Alternatives for CDI:
Mild cases: Vancomycin 125 mg PO q6h
Recurrent cases: Fidaxomicin
Metronidazole vs. Vancomycin for CDI
| Parameter | Metronidazole | Vancomycin (PO) |
|---|---|---|
| Cost | $ | $$$$ |
| Efficacy (mild CDI) | 78% | 81% |
| Systemic Absorption | Minimal (gut-targeted) | Minimal |
| Side Effects | Metallic taste, nausea | Rare |
| Recurrence Rate | 25-30% | 15-20% |
Patient Counseling Essentials
"Avoid ALL alcohol - including sauces, perfumes, and hand sanitizers."
"Take with food to reduce nausea."
"Dark urine is normal (drug metabolite)."
"Stop for neurological symptoms (dizziness, numbness)."
💡 Pro Tip: For dental infections, use topical metronidazole gel (0.75%) in periodontal pockets to reduce systemic exposure.
Prescribing Status: Widely available; monitor for resistance in Bacteroides (>10% in some regions). Report adverse events to FDA MedWatch.
Comments
Post a Comment